Skip to Main Content

Paper Details

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Cancer Discov
299
2017
BRCA2, Cell, DNA repair, DNA repair mutations, PALB2, PARP, Prostate Cancer, cfDNA, circulating cell-free DNA, germline, homologous recombination DNA, metastatic prostate cancer, olaparib, patient, patients, platinum, tumor
Author NameAffiliation
Joaquin MateoThe Institute of Cancer Research
Joaquin MateoThe Royal Marsden NHS Foundation Trust
Wei YuanThe Institute of Cancer Research
Susana MirandaThe Institute of Cancer Research
Raquel Perez-LopezThe Institute of Cancer Research
Raquel Perez-LopezThe Royal Marsden NHS Foundation Trust
Dan R RobinsonThe University of Michigan ann arbor
Penny FlohrThe Institute of Cancer Research
Gunther BoysenThe Institute of Cancer Research
Matthew ClarkeThe Institute of Cancer Research
Zafeiris ZafeiriouThe Institute of Cancer Research
Zafeiris ZafeiriouThe Royal Marsden NHS Foundation Trust
Adam SharpThe Institute of Cancer Research
Adam SharpThe Royal Marsden NHS Foundation Trust
Nina TunariuThe Institute of Cancer Research
Nina TunariuThe Royal Marsden NHS Foundation Trust
Arul M ChinnaiyanThe University of Michigan ann arbor
Arul M ChinnaiyanThe University of Michigan ann arbor
Suzanne CarreiraThe Institute of Cancer Research
Johann S de BonoThe Institute of Cancer Research
Johann S de BonoThe Royal Marsden NHS Foundation Trust
  • 1 - 21

Datasets

Release 1.2